CISPLATIN INJECTION 1 MG — DIN 02393832
CISPLATIN : 1 MG · STRIDES PHARMA CANADA INC · SOLUTION · wholesale supply in Canada
Health Canada status: APPROVED
What is CISPLATIN INJECTION?
CISPLATIN INJECTION 1 MG contains CISPLATIN : 1 MG. It is listed in the Health Canada Drug Product Database under DIN 02393832, held by STRIDES PHARMA CANADA INC, supplied as SOLUTION for INTRAVENOUS administration. Health Canada currently lists it as approved, status dated 28-Jul-2020. Nexara Health is a licensed Canadian wholesale distributor (DEL 3-002896-A). This DIN is not currently being marketed in Canada, so it is sourced to order where a compliant route exists rather than held in stock.
What is CISPLATIN INJECTION used for?
CISplatin Injection is indicated as palliative therapy, to be employed in addition to other modalities, or in established combination therapy with other chemotherapeutic agents in Metastatic Testicular Tumors, Metastatic Ovarian Tumors, and Advanced Bladder Cancer.
Authorized indication as written in the Health Canada product monograph. For healthcare professionals and licensed purchasers; this is not medical advice.
How much does Cisplatin cost around the world?
Cisplatin is listed on 8 of the national price registers Nexara ingests. Each country publishes on a different basis, so those figures are not comparable with one another — or with a Canadian wholesale price.
What a market publishes matters more than the number it publishes. Australia publishes a ex-manufacturer; Greece publishes a producer price (ex-factory); Norway publishes a max AUP (pharmacy retail). Comparing an ex-factory ceiling against a pharmacy public price tells you nothing about either, and comparing either against a Canadian landed cost tells you less.
| Market | Price basis published there | Brands | Packs listed | Range |
|---|---|---|---|---|
| Saudi Arabia | public | 7 | 13 | SAR███.██ |
| South Africa | single exit price | 10 | 11 | ZAR███.██ |
| Romania | max producer price | 1 | 4 | RON███.██ |
| United Kingdom | hospital | 3 | 3 | GBP███.██ |
| Australia | ex-manufacturer | 1 | 2 | AUD███.██ |
| Norway | max AUP (pharmacy retail) | 1 | 2 | NOK███.██ |
| United Arab Emirates | public | 1 | 1 | AED███.██ |
| Greece | producer price (ex-factory) | 1 | 1 | EUR███.██ |
37 pack listings across 25 brand entries and 7 price bases, refreshed 08 Sep 2026. Ranges span every Cisplatin pack in that market, so a high figure is usually a larger pack rather than the same product.
Canada publishes no comparable public list price. For a delivered Canadian price on a licensed account, verify your licence — it takes about a minute.
Is there a generic Cisplatin in Canada, and who makes it?
Every market authorization holder with a Canadian DIN for this molecule, and how many of their listings Health Canada currently shows as marketed.
12 holders have a Canadian DIN containing Cisplatin, across 13 DINs, of which 4 are currently marketed. Marketed count is the number that matters: an approval that is not marketed cannot be bought.
| Market authorization holder | DINs | Marketed | Brand names | Position |
|---|---|---|---|---|
| ACCORD HEALTHCARE INC | 1 | 1 | CISPLATIN INJECTION, BP | Sourceable in Canada |
| HIKMA CANADA LIMITED | 1 | 1 | CISPLATIN INJECTION BP | Sourceable in Canada |
| PFIZER CANADA ULC | 1 | 1 | CISPLATIN INJECTION BP | Sourceable in Canada |
| TEVA CANADA LIMITED | 1 | 1 | CISPLATIN INJECTION | Sourceable in Canada |
| DAVID BULL LABORATORIES (PTY) LTD. | 2 | 0 | CISPLATIN INJ 0.5MG/ML, CISPLATIN INJ 1MG/ML | No marketed DIN |
| BRISTOL LABS DIVISION OF BRISTOL-MYERS SQUIBB | 1 | 0 | PLATINOL AQ INJ 1MG/ML | No marketed DIN |
| FRESENIUS KABI CANADA LTD | 1 | 0 | CISPLATIN INJECTION | No marketed DIN |
| MYLAN PHARMACEUTICALS ULC | 1 | 0 | CISPLATIN INJECTION, MYLAN STD. | No marketed DIN |
| OMEGA LABORATORIES LIMITED | 1 | 0 | CISPLATIN INJECTION | No marketed DIN |
| PHARMASCIENCE INC | 1 | 0 | PMS-CISPLATIN | No marketed DIN |
| SANDOZ CANADA INCORPORATED | 1 | 0 | CISPLATIN INJECTION BP | No marketed DIN |
| STRIDES PHARMA CANADA INC | 1 | 0 | CISPLATIN INJECTION | No marketed DIN |
Health Canada’s Drug Product Database does not flag which listing is the originator and which are subsequent-entry products, so Nexara does not label them here. Interchangeability is determined provincially, not federally — confirm for your province before a formulary switch. Nexara can confirm which of these is actually obtainable, and on what lead time, per order.
How is it supplied and stored?
Pack configuration, storage class and the handling constraints that drive cold-chain planning. One DIN can cover more than one pack size, and the pack — not the DIN — is what gets priced, shipped and invoiced.
| Strength on the label | 1 MG |
|---|---|
| Dosage form | SOLUTION |
| Route | INTRAVENOUS |
| Pack configuration (monograph) | null |
| Storage | null |
Before an order line is unambiguous Nexara needs the strength, the pack size and the presentation.
Substance and classification
| Active substance | Cisplatin |
|---|---|
| ATC code | L01XA01 |
| AHFS class | 10:00.00 |
| Biosimilar biologic | No |
Health Canada record and identifiers
The regulatory facts straight from the Drug Product Database, plus every identifier form Nexara accepts on a purchase order. A DIN written without its leading zeros is the commonest reason an order line fails to match.
| DIN (8-digit, as used in ordering) | 02393832 |
|---|---|
| DIN (unpadded, as printed on some documents) | 2393832 |
| Brand name | CISPLATIN INJECTION |
| Generic / active ingredient | CISPLATIN : 1 MG |
| Market authorization holder | STRIDES PHARMA CANADA INC |
| Health Canada schedule | Prescription |
| ATC code | L01XA01 |
| ATC anatomical main group | L — Antineoplastic and immunomodulating agents |
| ATC therapeutic subgroup | L01XA |
| Current status | APPROVED |
| Status date | 28-Jul-2020 |
| Status source | Live Health Canada DPD sync |
Verify on the primary sources
What can be used instead?
Alternatives on every axis a buyer actually considers — the same molecule in another presentation, the same class, an adjacent class, or a fixed-dose combination. Every row is led by the marketed DIN count, because that is what can be bought this week.
1 · Same molecule, other Canadian presentations
4 of 13 Canadian DINs for this molecule are currently marketed. Marketed products are listed first.
| Product | Strength | Form | Holder | Health Canada status | DIN |
|---|---|---|---|---|---|
| CISPLATIN INJECTION | 1.0 MG | SOLUTION | TEVA CANADA LIMITED | MARKETED | 02403188 |
| CISPLATIN INJECTION BP | 1 MG | SOLUTION | HIKMA CANADA LIMITED | MARKETED | 02536285 |
| CISPLATIN INJECTION BP | 1 MG | SOLUTION | PFIZER CANADA ULC | MARKETED | 02126613 |
| CISPLATIN INJECTION, BP | 1 MG | SOLUTION | ACCORD HEALTHCARE INC | MARKETED | 02355183 |
| CISPLATIN INJ 0.5MG/ML | .5 MG | LIQUID | DAVID BULL LABORATORIES (PTY) LTD. | CANCELLED POST MARKET | 00644293 |
| CISPLATIN INJ 1MG/ML | 1 MG | LIQUID | DAVID BULL LABORATORIES (PTY) LTD. | CANCELLED POST MARKET | 00692743 |
| CISPLATIN INJECTION | 1 MG | SOLUTION | FRESENIUS KABI CANADA LTD | APPROVED | 02409186 |
| CISPLATIN INJECTION | 1 MG | SOLUTION | OMEGA LABORATORIES LIMITED | APPROVED | 02422034 |
| CISPLATIN INJECTION BP | 1 MG | SOLUTION | SANDOZ CANADA INCORPORATED | CANCELLED POST MARKET | 02366711 |
| CISPLATIN INJECTION, MYLAN STD. | 1 MG | SOLUTION | MYLAN PHARMACEUTICALS ULC | CANCELLED POST MARKET | 02396890 |
2 · Same class — other molecules in ATC L01XA
| Molecule | Canadian brands | DINs | Marketed | Sourceable |
|---|---|---|---|---|
| Oxaliplatin | ACT OXALIPLATIN · ELOXATIN · OXALIPLATIN · OXALIPLATIN FOR INJECTION · +6 more | 22 | 5 | Yes |
| Cisplatin | CISPLATIN INJ 0.5MG/ML · CISPLATIN INJ 1MG/ML · CISPLATIN INJECTION · CISPLATIN INJECTION BP · +4 more | 13 | 4 | Yes |
| Carboplatin | CARBOPLATIN INJECTION · CARBOPLATIN INJECTION BP · CARBOPLATIN INJECTION LIQ 10MG/ML · CARBOPLATIN INJECTION, BP · +2 more | 10 | 3 | Yes |
A molecule with zero marketed DINs cannot be sourced domestically, however many approvals it holds — if one of these sits on a formulary or in an older protocol, that is the line to check.
3 · Adjacent classes in ATC L01X
| ATC subgroup | Molecules | DINs | Marketed |
|---|---|---|---|
| L01XX | Aflibercept · Altretamine · Amsacrine · Anagrelide · Arsenic Trioxide · +13 more | 48 | 23 |
| L01XG | Bortezomib · Carfilzomib · Ixazomib | 30 | 18 |
| L01XK | Niraparib · Niraparib And Abiraterone · Olaparib · Talazoparib | 12 | 7 |
| L01XL | Axicabtagene Ciloleucel · Brexucabtagene Autoleucel · Ciltacabtagene Autoleucel · Idecabtagene Vicleucel · Lifileucel · +2 more | 8 | 5 |
| L01XJ | Glasdegib · Sonidegib · Vismodegib | 4 | 4 |
| L01XD | Aminolevulinic Acid · Methyl Aminolevulinate · Porfimer Sodium | 5 | 3 |
| L01XM | Enasidenib · Vorasidenib | 4 | 2 |
| L01XF | Tretinoin | 2 | 2 |
Not clinical advice. These tables describe what can be supplied in Canada, not what should be prescribed. Substitution within or across classes is a prescriber and pharmacist decision, and interchangeability is determined provincially.
What else is CISPLATIN INJECTION called?
The same molecule, Cisplatin, is registered under other names elsewhere. Buyers and prescribers searching from outside Canada — or working from a foreign prescription or tender document — often know it by one of these:
| Name | Script | Registered in |
|---|---|---|
| Cisplatin Accord | Latin | Australia, Norway |
Names are taken from national medicine registers and published price lists. A product registered abroad is not authorized for sale in Canada unless it holds its own DIN; import is possible only through the routes Health Canada permits.
How can I get it?
This product is approved by Health Canada but not yet marketed in Canada, so there is no Canadian supply to draw on today. Nexara can tell you whether it has been launched, and can look at supply from other markets where a Canadian pack is not required or where importation is permitted.
Ordering questions
Who can buy this from Nexara?
Licensed entities only. Nexara holds Health Canada establishment licence DEL 3-002896-A and ships only to a licensed address. Patients and unlicensed buyers are routed to a partner pharmacy.
Is there a minimum order?
Yes, set per product line and per pack multiple rather than on the order total, so you are never asked to buy a part-pack. The minimum for this line is confirmed with your quote.
What is the lead time?
Confirmed per order at quotation, and it depends on current stock position and whether the product is in shortage.
Why is there no price on this page?
Nexara quotes a delivered Canadian price per order, against a verified licence. Foreign list prices are published on incompatible bases and are not a guide to what any buyer can obtain here, so this page shows which markets list the molecule and on what basis, and nothing more.
Can Nexara supply this for a clinical trial?
Yes — comparator and background-therapy supply, including sourcing from other markets where a Canadian pack will not satisfy the protocol. Clinical trial supply.